Skip to content
PodSubs
ShowsPeopleGuestsJobsNewsEvents
More
BlogPodCred
Menu
ShowsPeopleGuestsJobsNewsEventsBlogPodCredNetworksSign in
Join nowSign in
  • Shows
  • People
  • Jobs
  • News
  • More
    • Guests
    • Events
    • Blog
    • PodCred
    • Networks
    Join nowSign in

ASCO Guidelines

ASCO Guidelines artwork

Medical Therapy for Hormone Receptor-Positive, HER2-Negative Stage I-III Breast Cancer: ASCO Living Guideline 2026.1.0

Oct 29, 202614 minAudio
ShareXLinkedInFacebookWhatsAppEmail

Dr. Jennifer Caswell-Jin and Dr. Michael Hassett join the podcast to introduce the new living guideline, "Medical Therapy for Hormone Receptor-Positive, HER2-Negative Stage I-III Breast Cancer." As co-chairs of the expert panel, they provide a comprehensive overview of the guideline's scope and purpose, which consolidates recommendations from multiple previous ASCO guidelines into a single, regularly updated resource. Drs. Caswell-Jin and Hassett discuss the key recommendations for neoadjuvant and adjuvant therapies, including chemotherapy, endocrine therapy, and targeted therapies like CDK4/6 inhibitors and olaparib. They explain the guideline's novel framework for estimating prognosis and using absolute risk to guide individualized treatment decisions. The discussion also covers ongoing research the panel is monitoring for future updates, such as the Keynote-756 and lidERA trials, and the potential role of circulating tumor DNA tests. Read the full living guideline, "Medical Therapy for Hormone Receptor-Positive, HER2-Negative Stage I-III Breast Cancer: ASCO Living Guideline, Version 2026 1.0," at www.ascopubs.org/guidelines." LINK TO FULL TRANSCRIPT

Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.

Hosts and Guests

Nobody is credited on this episode yet.

Credit the people on this episode

Be the first to rate this episode

More episodes

All episodes
  1. Breast Cancer Follow-Up and Surveillance After Primary Treatment Guideline Update

    Aug 26, 202620 minAudio

    Drs. Zeina Nahleh and Maryam Lustberg join the podcast to discuss the updated ASCO guideline on breast cancer follow-up and surveillance after primary treatment. Drs. Nahleh and Lustberg explain the new risk-stratified...

    Credit the people on this episode

  2. Systemic Treatment of Ovarian Cancer Recurrence: ASCO Living Guideline 2026.1.0

    Aug 24, 202621 minAudio

    Drs. Jamie Lesnock and Sara Bouberhan join the podcast to discuss the first ASCO guideline on systemic treatment for recurrent ovarian cancer. They provide a comprehensive overview of the evidence-based recommendations...

    Credit the people on this episode

  3. Therapy for Stage IV NSCLC With Driver Alterations: ASCO Living Guideline Update 2026.3.2

    Jul 28, 20269 minAudio

    Dr. Sonam Puri joins the podcast to share the update to the living guideline on stage IV NSCLC with driver alterations. Dr. Puri discusses the practice-changing evidence reviewed for both NTRK rearrangements, including...

    Credit the people on this episode

  4. Treatment of Multiple Myeloma: ASCO Living Guideline Update 2026.1.1

    Jun 29, 202618 minAudio

    Dr. Rahul Banerjee joins the podcast to discuss the latest update to the living guideline on the treatment of multiple myeloma. He explains how sensational results from the MajesTEC-3 trial, which evaluated teclistamab...

    Credit the people on this episode

  5. Circulating Tumor DNA Testing in Solid Tumors and Lymphoma Guideline

    Jun 18, 202618 minAudio

    Drs. Tina Lockwood and Stacy Gray share the newly released evidence-based guideline on circulating tumor DNA (ctDNA) testing from ASCO. They highlight recommendations on when ctDNA testing should be offered - including...

    Credit the people on this episode